Scholarlink

<p>Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (<i>n</i> = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age &lt;75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, <i>p</i> = 0.03) and extramedullary disease (22% vs. 40%, <i>p</i> = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, <i>p</i> = 0.27), any-grade ICANS (19% vs. 13%, <i>p</i> = 0.12), and overall response rate (62% vs. 53%, <i>p</i> = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Outcomes of elderly patients with relapsed refractory multiple myeloma (RRMM) treated with teclistamab: a multicenter study from the U.S. Multiple Myeloma Immunotherapy Consortium

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年5月9日

查看全文
  • Oren Pasvolsky,
  • Danai Dima,
  • Lei Feng,
  • Wenli Dong,
  • Tiffany Richards,
  • James A. Davis,
  • Aimaz Afrough,
  • Mariola Vazquez-Martinez,
  • Aishwarya Sannareddy,
  • Utkarsh Goel,
  • Rahul Banerjee,
  • Jack Khouri,
  • Frances Cervoni,
  • Mahmoud R. Gaballa,
  • Alex Lieberman-Cribbin,
  • Masooma Shifa Rana,
  • Kelley Julian,
  • Christopher J. Ferreri,
  • Leyla Shune,
  • Shaun DeJarnette,
  • Evguenia Bhurtel,
  • Sandra Susanibar Adaniya,
  • Andrew Portuguese,
  • Hitomi Hosoya,
  • Lekha Mikkilineni,
  • Gurbakhash Kaur,
  • Adriana Rossi,
  • Megan M. Herr,
  • Daniel Schrum,
  • Chenyu Lin,
  • Shahzad Raza,
  • Yi Lin,
  • Shonali Midha,
  • Nadeem Omar,
  • Shebli Atarsh,
  • Joseph McGuirk,
  • Douglas Sborov,
  • Peter Voorhees,
  • Faiz Anwer,
  • Melissa Alsina,
  • Ciara Freeman,
  • Alfred L. Garfall,
  • Beatrice M. Razzo,
  • Surbhi Sidana,
  • Andrew J. Cowan,
  • Larry D. Anderson Jr,
  • Doris K. Hansen,
  • Shambavi Richard,
  • Krina K. Patel,
  • Hans C. Lee,
  • Ariel Grajales-Cruz

摘要

Teclistamab, a BCMA-directed bispecific antibody, received regulatory approval for relapsed/refractory multiple myeloma (RRMM) based on the MajesTEC-1 study. Despite the fact that myeloma is primarily a cancer of elderly adults, only 15% of MajesTEC-1 participants (n = 24) were ≥75 years old. In this multicenter retrospective study, we report real-world outcomes of a large cohort of older RRMM patients treated with teclistamab. Of 385 analyzed patients, 83 (22%) were in the older group (age ≥75) and 302 (78%) in the younger group (age <75). Compared to the younger group, the older group had less adverse baseline disease characteristics, including a lower incidence of high-risk cytogenetics (44.6% vs. 57.9%, p = 0.03) and extramedullary disease (22% vs. 40%, p = 0.02). There were no significant differences in rates of any-grade CRS (52% vs. 59%, p = 0.27), any-grade ICANS (19% vs. 13%, p = 0.12), and overall response rate (62% vs. 53%, p = 0.17) between the older and younger groups. In multivariable analysis, age was not significantly associated with survival outcomes. Our findings suggest that teclistamab is safe and efficacious in well-selected patients ≥75 years old, and advanced age alone should not preclude teclistamab administration.